[Severe cytomegalovirus enteritis in AIDS. Favorable outcome of medical treatment].
Haas
C
C
Marteau
P
P
Roudière
L
L
Gisselbrecht
M
M
Lowenstein
W
W
Durand
H
H
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D002446:Celiac Disease / Q000628:therapy*; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D019888:Nelfinavir / Q000008:administration & dosage; D010288:Parenteral Nutrition; D010419:Pentamidine; D011504:Protein-Losing Enteropathies / Q000628:therapy*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D018119:Stavudine / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D017245:Foscarnet; D010419:Pentamidine; D018119:Stavudine; D019888:Nelfinavir; D015774:Ganciclovir